AQST Shareholders Have Opportunity to Lead Aquestive Therapeutics, Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today!
Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against Aquestive Therapeutics, Inc. (NASDAQ:AQST) for alleged violations of federal securities laws. The lawsuit claims Aquestive made false and misleading statements about the approval timeline for its Anaphylm NDA, failing to disclose significant human factors risks impacting regulatory approval. Investors who purchased AQST securities between June 16, 2025, and January 8, 2026, are encouraged to join the lawsuit and have until May 4, 2026, to request to be appointed as lead plaintiff.
How this was made

The 30-second read
Why it matters
The lawsuit's allegations could lead to stock price volatility, increased scrutiny, and potential delays or setbacks in product approval processes.
Market read
The legal action poses a material risk to AQST's stock performance and investor confidence, with potential ripple effects in the biotech sector.
What to watch
Potential positive developments in drug approval processes or settlement negotiations that could mitigate legal risks.
Background
Aquestive Therapeutics is facing a class action lawsuit alleging false and misleading statements regarding its NDA approval timeline, with significant legal and regulatory implications.
Ticker impact
High relevance due to legal action and potential impact on stock price.
Moderate to significant decline in short-term stock price, possibly 10-15% if legal proceedings intensify.
Legal actions and allegations of securities law violations typically lead to negative investor sentiment and stock price declines, especially when the news is recent and involves material disclosures.
Market effects
Potential negative impact on the life sciences sector, especially biotech firms with similar regulatory and legal risks.
Limited regional impact; primarily affects US-based biotech stocks.
Low; specific to US securities and legal environment.
Counterpoint
Legal action may be a temporary setback; if AQST can demonstrate compliance and resolve issues, the stock could recover.
Key entities
- Law FirmBronstein, Gewirtz & Grossman, LLC
Law firm representing shareholders in the class action lawsuit.
- Biotech CompanyAquestive Therapeutics, Inc.
The subject of the lawsuit, involved in drug development and regulatory approval.





